Emerging targeted therapies in non-small cell lung cancer

Nabin Khanal, Apar Kishor P Ganti

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer-related deaths in United States, accounting for more than one-fourth of the deaths annually. Although comparatively rare and relatively less studied, genetic abnormalities other than epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and Kirsten rat sarcoma (KRAS) mutations account for significant proportion of the driver mutations identified thus far. The targeted agents against B-rapidly accelerated fibrosarcoma (BRAF) V600E mutation, MNNG-HOS transforming gene (MET) pathway, ROS1 rearrangement, rearranged during transfection (RET) rearrangement, and HER2 pathways offer promising therapeutic options. Recruiting patients with these rarer mutations to well-designed, large multicenter trials to further validate the use of targeted agents remains a challenge. The clinical data and ongoing trials with these agents are reviewed in this article.

Original languageEnglish (US)
Pages (from-to)177-187
Number of pages11
JournalExpert review of anticancer therapy
Volume16
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Mutation
Therapeutics
Methylnitronitrosoguanidine
Fibrosarcoma
Oncogenes
Epidermal Growth Factor Receptor
Sarcoma
Multicenter Studies
Transfection
Lung Neoplasms
Neoplasms

Keywords

  • BRAF V600E
  • HER2 expression
  • MET pathway
  • Non-small cell lung cancer
  • ROS1 rearrangement
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Emerging targeted therapies in non-small cell lung cancer. / Khanal, Nabin; Ganti, Apar Kishor P.

In: Expert review of anticancer therapy, Vol. 16, No. 2, 01.02.2016, p. 177-187.

Research output: Contribution to journalReview article

@article{059557db02864c9989c31be3029fbb29,
title = "Emerging targeted therapies in non-small cell lung cancer",
abstract = "Lung cancer is the leading cause of cancer-related deaths in United States, accounting for more than one-fourth of the deaths annually. Although comparatively rare and relatively less studied, genetic abnormalities other than epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and Kirsten rat sarcoma (KRAS) mutations account for significant proportion of the driver mutations identified thus far. The targeted agents against B-rapidly accelerated fibrosarcoma (BRAF) V600E mutation, MNNG-HOS transforming gene (MET) pathway, ROS1 rearrangement, rearranged during transfection (RET) rearrangement, and HER2 pathways offer promising therapeutic options. Recruiting patients with these rarer mutations to well-designed, large multicenter trials to further validate the use of targeted agents remains a challenge. The clinical data and ongoing trials with these agents are reviewed in this article.",
keywords = "BRAF V600E, HER2 expression, MET pathway, Non-small cell lung cancer, ROS1 rearrangement, targeted therapy",
author = "Nabin Khanal and Ganti, {Apar Kishor P}",
year = "2016",
month = "2",
day = "1",
doi = "10.1586/14737140.2016.1126514",
language = "English (US)",
volume = "16",
pages = "177--187",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Emerging targeted therapies in non-small cell lung cancer

AU - Khanal, Nabin

AU - Ganti, Apar Kishor P

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Lung cancer is the leading cause of cancer-related deaths in United States, accounting for more than one-fourth of the deaths annually. Although comparatively rare and relatively less studied, genetic abnormalities other than epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and Kirsten rat sarcoma (KRAS) mutations account for significant proportion of the driver mutations identified thus far. The targeted agents against B-rapidly accelerated fibrosarcoma (BRAF) V600E mutation, MNNG-HOS transforming gene (MET) pathway, ROS1 rearrangement, rearranged during transfection (RET) rearrangement, and HER2 pathways offer promising therapeutic options. Recruiting patients with these rarer mutations to well-designed, large multicenter trials to further validate the use of targeted agents remains a challenge. The clinical data and ongoing trials with these agents are reviewed in this article.

AB - Lung cancer is the leading cause of cancer-related deaths in United States, accounting for more than one-fourth of the deaths annually. Although comparatively rare and relatively less studied, genetic abnormalities other than epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and Kirsten rat sarcoma (KRAS) mutations account for significant proportion of the driver mutations identified thus far. The targeted agents against B-rapidly accelerated fibrosarcoma (BRAF) V600E mutation, MNNG-HOS transforming gene (MET) pathway, ROS1 rearrangement, rearranged during transfection (RET) rearrangement, and HER2 pathways offer promising therapeutic options. Recruiting patients with these rarer mutations to well-designed, large multicenter trials to further validate the use of targeted agents remains a challenge. The clinical data and ongoing trials with these agents are reviewed in this article.

KW - BRAF V600E

KW - HER2 expression

KW - MET pathway

KW - Non-small cell lung cancer

KW - ROS1 rearrangement

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84957429744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957429744&partnerID=8YFLogxK

U2 - 10.1586/14737140.2016.1126514

DO - 10.1586/14737140.2016.1126514

M3 - Review article

C2 - 26618563

AN - SCOPUS:84957429744

VL - 16

SP - 177

EP - 187

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 2

ER -